TransThera Sciences (Nanjing), Inc. (TransThera-B) disclosed that it repurchased 105,000 H shares on 22 July 2026 via the Hong Kong Stock Exchange. The shares were bought at prices ranging from HKD 10.85 to HKD 10.93, representing a volume-weighted average of HKD 10.91 per share and an aggregate consideration of HKD 1.15 million.

Following the transaction: • Issued shares outstanding (excluding treasury shares) decreased to 312.29 million. • Treasury shares increased to 396,000, while total issued shares remained unchanged at 312.69 million. • The repurchased shares are being held as treasury stock; none have been cancelled.

Repurchase mandate status: • Shareholder mandate granted: 18 June 2026. • Authorised shares under mandate: 31.27 million. • Cumulative shares repurchased under mandate: 396,000, equal to 0.13 % of the issued share base at the mandate date. • Moratorium on new share issues or treasury share sales remains in force until 21 August 2026.

Management confirmed that the repurchase was duly authorised by the board, executed in accordance with Hong Kong Main Board rules, and funded with funds already received by the company.